Elite Pharmaceuticals Inc (ELTP)

[no2koolaid]

This is why Vyvance has a much larger potential market. With what Elite might be able to do to develop a Vyvanse ANDA puts it in great position to capture market share early. As for the reason to engage PFE in some discussion? Not sure. Still, in the link you shared there is this highlight that indicates Elite might be able to create its own ANDA...

But because Vyvanse requires a rate-limited step of enzymatic conversion to become active amphetamine, it may be harder for users to achieve the desired surge of euphoria, even if they snort or inject it.3 In fact, a study in the Journal of Psychopharmacology found that when Vyvanse was administered via injection in doses as high as 50mg, it did not produce significant euphoric effects. On a “drug likability” scale, subjects felt a much greater drug-like “rush” from d-amphetamine than from Vyvanse. The study also noted that it was very difficult to extract the active amphetamine from the product through crushing.4

This could, therefore, discourage people from abusing it. The journal Pharmacy and Therapeutics noted that Vyvanse’s structure as a prodrug may offer a lower potential for abuse and reduces the risk of food or drug interactions. It is also the only stimulant with FDA-approved abuse-deterrent labeling.

This needs to be a point made in the questions for Nasrat in the next CC. But let's be clear, he already knows and he knows some investors know. We just want to let him know there is investor critical mass in support. OBTW: He will not and should not let the competitive world know what the company is working on, that would be managerial malfeasance. But he can dance with the question and should know the language of inference through plausible deniability.